BAUSCH + LOMB CORP (BLCO) Stock News
NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD
BLCO Latest News, Press Relases and Analysis
Wednesday's session: gap up and gap down stocks
Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
3 Profitable Stocks Walking a Fine Line
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
Mentions: BLCO.CA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such...
Crypto Influencer Anthony ‘Pomp’ Pompliano-Led SPAC Files for IPO
A blank-check company led by Anthony Pompliano, a cryptocurrency influencer and podcaster, has filed for an initial public offering to raise $200 million.
Why Bausch + Lomb (BLCO) Shares Are Falling Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall Street's estimates, leading to an EPS miss. On the other hand, it was good to see Bausch + Lomb provide full-year revenue guidance that slightly beat analysts' expectations, although raising full-year revenue guidance after missing on revenue often raises questions. Overall, this quarter could have been better.
Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch + Lomb Announces First-Quarter 2025 Results
Mentions: BLCO.CA
CVS Health (CVS) Earnings Expected to Grow: Should You Buy?
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CVS
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
Mentions: BLCO.CA
BLCO or DHR: Which Is the Better Value Stock Right Now?
BLCO vs. DHR: Which Stock Is the Better Value Option?
Mentions: DHR
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: RVTY
Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts?
We recently published a list of the 10 Most Undervalued Canadian Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against other undervalued Canadian stocks according to Wall Street analysts. As February was concluding, Reuters reported that Canada’s […]
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
Mentions: BLCO.CA
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
Mentions: BLCO.CA
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
Mentions: BLCO.CA
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent
Bausch and Lomb chairman and CEO Brent Saunders